表纸
市场调查报告书

人副流感病毒3型感染疾病:开发中产品分析

Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018

出版商 Global Markets Direct 商品编码 619904
出版日期 内容资讯 英文 33 Pages
订单完成后即时交付
价格
Back to Top
人副流感病毒3型感染疾病:开发中产品分析 Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018
出版日期: 2018年09月28日内容资讯: 英文 33 Pages
简介

人副流感病毒3型感染疾病,是引起婴幼儿呼吸器官疾病,威胁生命的感染疾病。主要的症状,包含发热和咳嗽,鼻涕,假膜性喉炎,细支气管炎,喘鸣,喉咙头痛等。主要的治疗药,有镇痛、解热用的成药 (OTC) 等。

本报告提供全球各国的人副流感病毒3型感染疾病的治疗药的开发中产品的开发情形相关分析,开发中产品的最新趋势,及临床实验的各阶段的产品一览,主要企业的简介,主要药物概要,最新的产业趋势 (临床实验调查中断中/已中止的产品等) 等。

目录

  • 简介
    • 分析范围
  • 口腔干燥症概要
  • 人副流感病毒3型感染疾病:治疗药的开发
    • 开发平台概要
    • 各企业的开发平台趋势
    • 各大学、研究机关的开发平台趋势
    • 企业开发中的产品
    • 在大学、研究机关开发中的产品
  • 人副流感病毒3型感染疾病:治疗药的评估
    • 各标的
    • 各作用机制
    • 各给药途径
    • 各分子类型
  • 人副流感病毒3型感染疾病:开发治疗药的企业
    • 3-V Biosciences Inc
    • Amarillo Biosciences Inc
    • Moderna Therapeutics Inc
  • 人副流感病毒3型感染疾病:药物的简介
    • 干扰素α
      • 产品概要
      • 作用机制
      • 研究开发 (R&D)的进展
    • mRNA-1653
    • Paradase
    • 人副流感病毒第一型、3型感染疾病,血凝素、神经胺糖酸酶抑制用小分子
    • TVB-3567
  • 人副流感病毒3型感染疾病:暂停的计划
  • 人副流感病毒3型感染疾病:开发中止的产品
  • 附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC10842IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.

Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.  

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Human Parainfluenza Virus 3 Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Parainfluenza Virus 3 Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Parainfluenza Virus 3 Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Human Parainfluenza Virus 3 Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Parainfluenza Virus 3 Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Parainfluenza Virus 3 Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Parainfluenza Virus 3 Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Parainfluenza Virus 3 Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Human Parainfluenza Virus 3 Infections - Overview
    • Human Parainfluenza Virus 3 Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Human Parainfluenza Virus 3 Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Human Parainfluenza Virus 3 Infections - Companies Involved in Therapeutics Development
    • 3-V Biosciences Inc
    • Amarillo Biosciences Inc
    • Moderna Therapeutics Inc
  • Human Parainfluenza Virus 3 Infections - Drug Profiles
    • interferon alpha - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mRNA-1653 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Paradase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Hemagglutinin and Neuraminidase for Human Parainfluenza Virus 1 and 3 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TVB-3567 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Human Parainfluenza Virus 3 Infections - Dormant Projects
  • Human Parainfluenza Virus 3 Infections - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Human Parainfluenza Virus 3 Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Human Parainfluenza Virus 3 Infections - Pipeline by 3-V Biosciences Inc, H2 2018
  • Human Parainfluenza Virus 3 Infections - Pipeline by Amarillo Biosciences Inc, H2 2018
  • Human Parainfluenza Virus 3 Infections - Pipeline by Moderna Therapeutics Inc, H2 2018
  • Human Parainfluenza Virus 3 Infections - Dormant Projects, H2 2018
  • Human Parainfluenza Virus 3 Infections - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Human Parainfluenza Virus 3 Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top